Chimeric antigen receptor T (CAR T) cell therapies - Yake Biotechnology
Alternative Names: CAR-T cell therapy - Yake BiotechnologyLatest Information Update: 28 Mar 2025
At a glance
- Originator Yake Biotechnology
- Class CAR-T cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Neuroblastoma; Solid tumours
Most Recent Events
- 12 Dec 2024 Phase-I/II clinical trials in Neuroblastoma (In adolescents, In adults, In children, In infants) in China (Parenteral) (NCT06836505)
- 12 Dec 2024 Phase-I/II clinical trials in Solid tumours (In adolescents, In adults, In children, In infants) in China (Parenteral) (NCT06836505)